Related Experiment Videos

Study of mutagenic activity of troxerutin, a flavonoid derivative

Toxicology Letters
|February 1, 1987
PubMed

Insights

Troxerutin, a flavonoid derivative, showed no mutagenic activity in four tests. In contrast, quercetin demonstrated mutagenicity, which was abolished by hydroxyethyl group substitution.

Area of Science:

  • Biochemistry
  • Toxicology
  • Pharmacology

Background:

  • Troxerutin is a flavonoid derivative used for vascular diseases.
  • Flavonoids, like quercetin, can exhibit varying biological activities, including potential mutagenicity.
  • Understanding the genotoxic profile of Troxerutin and related compounds is crucial for safety assessment.

Purpose of the Study:

  • To evaluate the mutagenicity of Troxerutin.
  • To compare the mutagenic potential of Troxerutin with quercetin and its aglycone, trihydroxyethylquercetin (THEQ).
  • To investigate the role of hydroxyethyl group substitution in modulating quercetin's mutagenicity.

Main Methods:

  • Ames test for bacterial reverse mutation.
  • V79/HPRT assay for gene mutation in mammalian cells.
  • In vitro metaphase analysis of human lymphocytes for chromosomal aberrations.
  • In vivo micronucleus test in mice for genotoxicity.

Main Results:

  • Troxerutin was found to be non-mutagenic across all four tested assays.
  • Quercetin tested positive for mutagenicity in the Ames test, V79 cells, and in vitro metaphase analysis.
  • Trihydroxyethylquercetin (THEQ) was negative in the Ames test.
  • Substitution of quercetin with hydroxyethyl groups at the 7, 3', and 4' positions eliminated its mutagenic activity.

Conclusions:

  • Troxerutin does not possess mutagenic properties.
  • The genotoxicity of quercetin is significantly reduced or abolished by hydroxyethylation.
  • Troxerutin is a safer alternative to quercetin concerning mutagenic potential.

Related Concept Videos